AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie current Portion of Long-Term Debt and Finance Leases ($M) ($M)
Form 10-Q / 10-K Consolidated Balance Sheets
Latest, FY2025
6,056
Period ended Dec 31, 2025
Change on a year earlier
-11.0%
6,804 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Current Portion of Long-Term Debt and Finance Leases ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,056 | -11.0% | Form 10-Q (filed 2026-08-03) ↗ |
| FY2024 | Dec 31, 2024 | 6,804 | -5.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 7,191 | +73.9% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 4,135 | -66.9% | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 12,481 | +47.4% | Form 10-K (filed 2023-02-17) ↗ |
| FY2020 | Dec 31, 2020 | 8,468 | +125.6% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 3,753 | +133.3% | Form 10-K (filed 2021-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 1,609 | -73.3% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 6,015 | +23,960.0% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 25 | -98.8% | Form 10-K (filed 2018-02-16) ↗ |
| FY2015 | Dec 31, 2015 | 2,025 | – | Form 10-K (filed 2017-02-17) ↗ |
Cite this data
StockData. (2026). AbbVie Current Portion of Long-Term Debt and Finance Leases ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/debt_lt_cur
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.